Risultati della ricerca - Marc‐Eric Halatsch
- Mostra 1 - 20 risultati su 22
- Vai alla pagina seguente
-
1
-
2
-
3
-
4
-
5
-
6
Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin di Richard E. Kast, Quentin A. Hill, Didier Wion, Håkan Mellstedt, Daniele Focosi, Georg Karpel‐Massler, Tim Heiland, Marc‐Eric Halatsch
Pubblicazione 2017Revisão -
7
TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners <i>in vitro</i> and <i>in vivo</i> di Georg Karpel‐Massler, Maïmouna Bâ, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin
Pubblicazione 2015Artigo -
8
Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis <i>in vitro</i> and <i>in vivo</i> di Georg Karpel‐Massler, Doruntina Ramani, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin
Pubblicazione 2016Artigo -
9
-
10
-
11
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy di Stephanie Ströbele, Matthias Schneider, Lukas Schneele, Markus D. Siegelin, Lisa Nonnenmacher, Shaoxia Zhou, Georg Karpel-Massle, Mike‐Andrew Westhoff, Marc‐Eric Halatsch, Klaus‐Michael Debatin
Pubblicazione 2015Artigo -
12
Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells di Georg Karpel‐Massler, Mike‐Andrew Westhoff, Shaoxia Zhou, Lisa Nonnenmacher, Annika Dwucet, Richard E. Kast, Max G. Bachem, Christian Rainer Wirtz, Klaus‐Michael Debatin, Marc‐Eric Halatsch
Pubblicazione 2013Artigo -
13
The effects of PI3K-mediated signalling on glioblastoma cell behaviour di Julia Langhans, Lukas Schneele, Nancy Trenkler, Hélène von Bandemer, Lisa Nonnenmacher, Georg Karpel‐Massler, Markus D. Siegelin, Shaoxia Zhou, Marc‐Eric Halatsch, Klaus‐Michael Debatin, Mike‐Andrew Westhoff
Pubblicazione 2017Artigo -
14
Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma di Maximilian Pruss, Annika Dwucet, Mine Tanriover, Michal Hlaváč, Richard E. Kast, Klaus‐Michael Debatin, Christian Rainer Wirtz, Marc‐Eric Halatsch, Markus D. Siegelin, Mike‐Andrew Westhoff, Georg Karpel‐Massler
Pubblicazione 2020Artigo -
15
Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i> di Georg Karpel‐Massler, Chang Shu, Lily Chau, Matei A. Banu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Yulian P. Ramirez, Alonzo H. Ross, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin
Pubblicazione 2015Artigo -
16
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro di Qiyu Cao, Annika Hajosch, Richard E. Kast, Christopher Loehmann, Michal Hlaváč, Pamela Fischer‐Posovszky, Hannah A. Strobel, Mike‐Andrew Westhoff, Markus D. Siegelin, Christian Rainer Wirtz, Marc‐Eric Halatsch, Georg Karpel‐Massler
Pubblicazione 2024Artigo -
17
A paired comparison between glioblastoma “stem cells” and differentiated cells di Matthias Schneider, Stephanie Ströbele, Lisa Nonnenmacher, Markus D. Siegelin, Melanie Tepper, Sebastien Stroh, Sebastian Hasslacher, Stefanie Enzenmüller, Gudrun Strauß, Bernd Baumann, Georg Karpel‐Massler, Mike‐Andrew Westhoff, Klaus‐Michael Debatin, Marc‐Eric Halatsch
Pubblicazione 2015Artigo -
18
Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma di Mike‐Andrew Westhoff, Shaoxia Zhou, Lisa Nonnenmacher, Georg Karpel‐Massler, Claudia Jennewein, Matthias Schneider, Marc‐Eric Halatsch, Neil O. Carragher, Bernd Baumann, Alexander Krause, Thomas Simmet, Max G. Bachem, Christian Rainer Wirtz, Klaus‐Michael Debatin
Pubblicazione 2013Artigo -
19
Phosphoinositide 3-Kinases Upregulate System x<sub>c</sub><sup>−</sup> <i>via</i> Eukaryotic Initiation Factor 2α and Activating Transcription Factor 4 – A Pathway Active in Gliobl... di Jan Lewerenz, Paul Baxter, Rebecca Kassubek, Philipp Albrecht, Joeri Van Liefferinge, Mike‐Andrew Westhoff, Marc‐Eric Halatsch, Georg Karpel‐Massler, Paul J. Meakin, John D. Hayes, Eleonora Aronica, Ilse Smolders, Albert C. Ludolph, Axel Methner, Marcus Conrad, Ann Massie, Giles E. Hardingham, Pamela Maher
Pubblicazione 2013Artigo -
20
A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 di Marc‐Eric Halatsch, Richard E. Kast, Georg Karpel‐Massler, Benjamin Mayer, Oliver Zolk, Bernd Schmitz, Angelika Scheuerle, Ludwig Maier, Lars Bullinger, Regine Mayer‐Steinacker, Carl J. Schmidt, Katharina Zeiler, Ziad Elshaer, Patricia Panther, Birgit Schmelzle, Anke Hallmen, Annika Dwucet, Markus D. Siegelin, Mike‐Andrew Westhoff, Kristine Beckers, Gauthier Bouche, Tim Heiland
Pubblicazione 2021Artigo
Strumenti per la ricerca:
Soggetti correlati
Cancer research
Biology
Glioblastoma
Medicine
Apoptosis
Biochemistry
Genetics
Pharmacology
Cell biology
Glioma
Chemistry
Gene
Temozolomide
Cancer
In vivo
Internal medicine
Programmed cell death
U87
Biotechnology
Immunology
Stem cell
Caspase
Signal transduction
XIAP
Antiemetic
Aprepitant
Cancer stem cell
Cell culture
Chemotherapy
Dacarbazine